In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

A whole genome in vivo CRISPR/Cas9 screen identifies TCEAL1 as a potential target to sensitise prostate cancer cells to docetaxel to improve the efficacy of chemotherapy. Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance. To ide...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Linda K Rushworth, Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, Holly Hall, Martin Bushell, Hing Y Leung, Rachana Patel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Life Science Alliance LLC 2020-12-01
coleção:	Life Science Alliance
Acesso em linha:	https://www.life-science-alliance.org/lookup/doi/10.26508/lsa.202000770
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!